First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Ligand Pharmaceuticals: the story is balanced — Partner drug regulatory approvals and launches - FDA/EMA decisions on drugs using Ligand technologies directly create…
★ Analysts see FY2027 revenue reaching $376M — +29.7% growth in a single year.
What Moves the Stock
1Partner drug regulatory approvals and launches - FDA/EMA decisions on drugs using Ligand technologies directly create new royalty streams (e.g., new Captisol-enabled oncology drug approvals)
2Clinical trial readouts for late-stage partnered programs - Phase 3 success/failure for drugs incorporating Ligand platforms determines future royalty potential
3New technology licensing deals and upfront payments - OmniAb or Captisol partnerships with major pharma create immediate revenue and validate platform value
4Quarterly royalty revenue performance from commercial products - sales trends for key royalty-generating drugs like Kyprolis indicate baseline revenue trajectory
5Acquisition activity - company historically acquires complementary royalty portfolios or technology platforms to expand revenue base
6Royalty revenue from partnered commercial products (estimated 50-60% of revenue) - includes Kyprolis, Evomela, and other approved drugs using Captisol technology
7Technology licensing and milestone payments (estimated 25-35%) - upfront fees and development milestones from pharmaceutical partners licensing OmniAb antibody discovery platform and Captisol solubilization technology
8Material sales and contract revenue (estimated 10-20%) - Captisol material supply to partners for clinical and commercial manufacturing
growth - The 27% revenue growth, asset-light royalty model, and exposure to pharmaceutical innovation attract growth investors seeking…
Rising interest rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples…
Watch on earnings: FDA calendar for partner drug approvals - tracks upcoming regulatory decisions for Captisol-enabled or OmniAb-derived drugs that create new royalty streams, Quarterly royalty revenue by product - monitors sales trends for key commercial products (Kyprolis, Evomela) and identifies emerging revenue contributors, Clinical trial progression rates for partnered programs - percentage of Phase 2 programs advancing to Phase 3 indicates pipeline quality and future royalty potential.
One Sentence Summary:
Ligand Pharmaceuticals: the story is balanced — partner drug regulatory approvals and launches - fda/ema decisions on drugs using ligand technologies directly create new royalty streams.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.